A statistically significant prolongation of the time to progression, from 3.7 to 5.6 months (log-rank p < 0.0012) and a statistically significant prolongation of median survival from 7.6 months to 9.1 months (log-rank p < 0.004) was observed in patients treated with gemcitabine/cisplatin compared to patients treated with cisplatin.